Sandostatin franchise maintaining share vs generic pressure
The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024
Additionally, early life stress induced both immediate as well as late effects
The result is faster healing of more types of injury than either peptide alone, which is why the Wolverine Stack is the protocol of choice for athletes coming back from surgery, professional fighters between camps, and high-performing executives recovering from years of accumulated wear-and-tear
It is intended for research purposes only and is not approved for human consumption, diagnostic, or therapeutic use